Cite
MLA Citation
M.J. Cork et al.. “Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study.” British journal of dermatology, vol. 184, 2021, pp. 857–870. http://access.bl.uk/ark:/81055/vdc_100129526866.0x000018